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ABSTRACT 
 
Context 
Autosomal dominant hypocalcemia types 1 and 2 (ADH1 and ADH2) are caused by germline 
gain-of-function mutations of the calcium-sensing receptor (CaSR) and its signaling partner, 
the G-protein subunit α11 (Gα11), respectively. Over 70 different gain-of-function CaSR 
mutations, but only 6 different gain-of-function Gα11 mutations are reported to date.  
Methods 
We ascertained two additional ADH families and investigated them for CaSR and Gα11 
mutations. The effects of identified variants on CaSR signaling were evaluated by transiently 
transfecting wild-type (WT) and variant expression constructs into HEK293 cells stably 
expressing CaSR (HEK-CaSR), and measuring intracellular calcium (Ca2+i) and MAPK 
responses following stimulation with extracellular calcium (Ca2+e). 
Results 
CaSR variants were not found, but two novel heterozygous germline Gα11 variants, 
p.Gly66Ser and p.Arg149His, were identified. Homology modelling of these revealed that the 
Gly66 and Arg149 residues are located at the interface between the Gα11 helical and 
GTPase domains, which is involved in guanine nucleotide binding, and this is the site of 
three other reported ADH2 mutations. The Ca2+i and MAPK responses of cells expressing 
the variant Ser66 or His149 Gα11 proteins were similar to WT cells at low Ca
2+
e, but 
significantly increased in a dose-dependent manner following Ca2+e stimulation, thereby 
indicating that the p.Gly66Ser and p.Arg149His variants represent pathogenic gain-of-
function Gα11 mutations. Treatment of Ser66- and His149-Gα11 expressing cells with the 
CaSR negative allosteric modulator NPS 2143 normalized Ca2+i and MAPK responses.  
Conclusion 
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Two novel ADH2-causing mutations that highlight the Gα11 interdomain interface as a 
hotspot for gain-of-function Gα11 mutations have been identified. 
 
 
 
Précis 
 
DNA sequencing of genes encoding CaSR and Gα11 in two ADH families, identified novel 
gain-of-function Gα11 p.Gly66Ser and p.Arg149His mutations, which are located at the Gα11 
interdomain interface. 
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INTRODUCTION 
 
Autosomal dominant hypocalcemia (ADH) is a disorder of systemic calcium homeostasis, 
which affects the parathyroid glands and kidneys, and is caused by increased sensitivity of 
the calcium-sensing receptor (CaSR) to extracellular calcium (Ca2+e) concentrations (1,2). 
The CaSR is a class C G-protein coupled receptor (GPCR), which plays a pivotal role in the 
parathyroid and renal regulation of Ca2+e (3) by activating the G-protein αq/11 family, which 
enhances phospholipase C (PLC) activity resulting in intracellular calcium (Ca2+i) 
mobilisation and activation of the phospho-ERK (pERK) arm of the MAPK signaling pathway 
(3,4) (Fig. 1A). ADH comprises two genetic variants, designated as ADH types 1 and 2 
(ADH1 and ADH2), which are caused by germline gain-of-function mutations in genes 
encoding the CaSR and G-protein subunit α11 (Gα11) proteins, respectively (1,2). ADH1 
(OMIM #601198) has been reported in association with >70 different CaSR mutations (5), 
and is characterised by hypocalcemia, hyperphosphatemia, hypomagnesemia, 
inappropriately low or normal PTH concentrations, and a relative or absolute hypercalciuria 
(1,6). In addition, some ADH1 patients may develop a Bartter-like syndrome with 
hypokalemic alkalosis, renal salt wasting and hyperreninemic hyperaldosteronism (7,8). 
ADH2 (OMIM #615361) has been described in seven probands (2,9-12), and these patients 
have a similar serum biochemical phenotype to that of ADH1 patients. However, ADH2 is 
associated with a milder urinary phenotype, with significantly reduced urinary calcium 
excretion compared to ADH1 (9). Moreover, short stature has been reported in two ADH2 
kindreds (9,12). Conversely, germline loss-of-function CaSR and Gα11 mutations lead to the 
opposite phenotypes of familial hypocalciuric hypercalcemia (FHH) types 1 and 2, 
respectively (1,2), which is characterized by lifelong elevations of serum calcium 
concentrations in association with normal or mildly raised serum PTH concentrations, and 
low urinary calcium excretion (calcium‐to‐creatinine clearance ratio <0.01) (13,14).   
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To date, four FHH2 and six ADH2 different mutations have been identified in the GNA11 
gene on chromosome 19p13.3 (Fig. 1B), which encodes Gα11, and studies of the location of 
such mutations has provided insight into Gα11 structure-function (2,9-11,15,16). Thus, FHH2 
and ADH2 mutations cluster within three regions (Fig. 1C): the Gα11-GPCR interaction 
region; the interdomain interface between the helical and GTPase domains; and the sites at 
which Gα11 interacts with Gβγ and PLC (2,9-11,15,16). This indicates that these three 
structural regions play a critical role in Gα11-mediated CaSR signaling. Additionally, previous 
studies of these mutations have indicated that CaSR negative allosteric modulators, which 
are known as calcilytic compounds, can normalize the gain-of-function caused by Gα11 
mutations both in vitro and in mouse models of ADH2 (17-19), and thus represent a potential 
targeted therapy for this disorder.  
 
Here, we report the clinical and genetic findings in two unrelated families with ADH, in whom 
novel heterozygous germline gain-of-function Gα11 mutations, were identified. 
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MATERIALS AND METHODS 
 
Patients and Families 
 
Family 1. This family comprised 3 affected members (a mother, her son and daughter) (Fig. 
2A). The son (individual II.1, Fig. 2A) at the age of 10 years was referred with a chronic 
motor tic disorder, which was subsequently diagnosed as Tourette syndrome. He was also 
experiencing paraesthesia, and biochemical investigations showed him to have a mildly low 
serum calcium of 2.12 mmol/L (normal 2.20-2.70 mmol/L) in association with an 
inappropriately normal plasma PTH of 2.8 pmol/L (normal 1.0-7.0 pmol/L) and insufficient 
serum 25-hydroxyvitamin D (25OHD) of 42 nmol/L (adequate >50 nmol/L). He had a normal 
serum phosphate concentration of 1.57 mmol/L (normal 0.90-1.80 mmol/L), magnesium of 
0.90 mmol/L (normal 0.70-1.0), creatinine of 59 mol/L (normal 28-63), alkaline phosphatase 
activity of 146 IU/L (normal 60-425), and low urinary calcium-to-creatinine ratio of 0.08 
mmol/mmol (normal 0.30-0.70). He was commenced on oral calcium and cholecalciferol, 
which increased his serum 25OHD to 87 nmol/L, however, his serum calcium remained low 
at 2.11 mmol/L. His mother and younger sister (Fig. 2A) were also found to be mildly 
hypocalcemic with serum calcium concentrations of 2.08 mmol/L and 2.15 mmol/L, 
respectively. This family was investigated for ADH as a possible cause of the mild 
hypocalcemia and leucocyte DNA was obtained from affected family members following 
informed consent for analysis of the CASR and GNA11 genes.  
 
Family 2. This family comprised 5 affected members (a mother and her 2 sisters, and her 
daughter and son) (Fig. 2B). The daughter (individual III.1, Fig. 2B) at the age of 38 years, 
was referred with a 6 month history of fatigue, myalgia, dizziness and bilateral hip pain. She 
had no history of paraesthesia, muscle cramps, seizures or renal calculi. She had not 
previously undergone neck surgery, and had no history of deafness, renal or cardiac 
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abnormalities, candidiasis or Addison’s disease. Her only co-morbidity was recently 
diagnosed autoimmune hypothyroidism, which was treated with levothyroxine 75 
micrograms daily. Her height was 170 cm and weight was 84.3 kg. Biochemical 
investigations showed her to have a low serum calcium of 1.97 mmol/L (normal 2.20-2.60) in 
association with an inappropriately normal plasma PTH of 4.1 pmol/L (normal 1.0-7.0), and a 
borderline low urine calcium to creatinine ratio of 0.30 mmol/mmol (normal 0.30–0.70), and a 
fractional excretion of calcium 0.01 (normal >0.01). She had a normal serum magnesium 
concentration of 0.78 mmol/L (normal 0.70-1.00), phosphate of 1.12 mmol/L (normal 0.70-
1.45), creatinine of 69 mol/L (normal 45-90), alkaline phosphatase activity of 45 U/L 
(normal 30-130), 25-hydroxyvitamin D of 125 nmol/L (normal>50 nmol/L), 1,25-
dihydroxyvitamin D of 111 pmol/L (normal 43-144), and thyroid stimulatory hormone (TSH) 
of 1.76  mU/L (normal 0.30-4.20). Thyroid peroxidase antibodies were elevated at >1518 
(normal <60 IU/ml), and anti-parathyroid antibodies, as assessed by indirect 
immunofluorescence (20), were not detected. Her hypocalcemia was initially treated with 
1.0-2.5 grams of oral elemental calcium daily. However, she remained hypocalcemic and 
also became hypomagnesemic (lowest serum magnesium = 0.62 mmol/L), and was 
commenced on alfacalcidol 1.0 microgram daily, as well as oral magnesium aspartate 10 
mmol twice daily. Her mother, brother and two maternal aunts were also hypocalcemic (Fig. 
2B), and these findings were suggestive of either ADH or familial isolated 
hypoparathyroidism. Leucocyte DNA was obtained from affected family members following 
informed consent for analysis of the CASR, GNA11, GCM2, GATA3, AIRE and PTH genes.  
 
Mutational Analysis  
Mutational analysis was performed according to the clinical indications using leucocyte DNA, 
and by Sanger sequencing of all coding exons and exon-intron boundaries, utilising exon-
specific primers (SigmaAldrich), the BigDye Terminator v3.1 Cycle Sequencing Kit (Life 
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Technologies), and an automated detection system (ABI3730 Automated capillary 
sequencer; Applied Biosystems), as previously reported (2,21). Investigation of potentially 
pathogenic variants was undertaken using the publicly accessible Genome Aggregation 
Database (gnomAD) database:  (https://gnomad.broadinstitute.org/) which is a dataset 
comprising 125,748 exome sequences and 15,708 whole-genome sequences from 
unrelated individuals. Predicted effects of the mutations was assessed using Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/) (22) and MutationTaster 
(http://www.mutationtaster.org/) (23). 
 
Protein Sequence Alignment and Three-Dimensional Modeling of Gα11 Structure  
Protein sequences of Gα11 orthologs and Gα paralogs were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (24). Gα11 three-dimensional modeling was 
undertaken using the reported three-dimensional structure of Gαq, which shares 90% identity 
at the amino acid level with Gα11 (2). Gαq was modelled in complex with the small molecule 
inhibitor YM-254890 (Protein Data Bank (PDB) accession no. 3AH8) (25) and also in 
complex with the phospholipase C β3 effector (PDB: 3OHM) (26). Molecular modeling was 
performed using The PyMOL Molecular Graphics System (Version1.2r3pre, Schrödinger, LL 
Pymol) (2). 
 
Cell Culture and Transfection 
Wild-type and mutant pBI-CMV2-GNA11 expression constructs were generated as 
described (2), and transiently transfected into HEK293 cells stably expressing CaSR (HEK-
CaSR) (2) using Lipofectamine 2000 (LifeTechnologies). The bidirectional pBI-CMV2 cloning 
vector was used as it facilitated the co-expression of Gα11 and GFP (2), and site-directed 
mutagenesis was used to generate the mutant GNA11 construct using the Quikchange 
Lightning Site-directed Mutagenesis kit (Agilent Technologies) and gene-specific primers 
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(SigmaAldrich), as described (16). Cells were maintained in DMEM-Glutamax media 
(ThermoFisher) with 10% fetal bovine serum (Gibco) and 400µg/mL geneticin 
(ThermoFisher) at 37ºC, 5% CO2. Successful transfection was confirmed by visualising GFP 
fluorescence using an Eclipse E400 fluorescence microscope with a Y-FL Epifluorescence 
attachment and a triband 4,6-diamidino-2-phenylindole-FITC-Rhodamine filter, and images 
captured using a DXM1200C digital camera and NIS Elements software (Nikon) (2,16). The 
expression of Gα11 and CaSR proteins was also determined by Western blot analysis using 
anti-Gα11 (Santa-Cruz), anti-GFP (SantaCruz), or anti-CaSR (AbCam) antibodies; calnexin 
expression was used as a loading control and detected using an anti-calnexin (Millipore) 
antibody. The Western blots were visualized using an Immuno-Star WesternC kit (BioRad) 
on a BioRad Chemidoc XRS+ system (2).  
 
Intracellular calcium measurements 
Ca2+e-induced Ca
2+
i responses were measured by Fluo-4 calcium assays as previously 
described (16). HEK-CaSR cells were plated in 12-well plates and transiently transfected 
with 1000µg/ml pBI-CMV2-GNA11. Following 24 hours incubation, cells were replated at 
30,000 cells/well in black walled 96-well plates (Corning). Cells were treated with serum-free 
media (SFM) overnight. Fluo-4 dye was prepared according to manufacturer’s instructions 
(Invitrogen), and cells loaded for 1 hour at 37°C. Baseline measurements were made and 
increasing concentrations of CaCl2 injected automatically into each well. Changes in Ca
2+
i 
were recorded on a PHERAstar instrument (BMG Labtech) at 37°C with an excitation filter of 
485nm and an emission filter of 520nm. The peak mean fluorescence ratio of the transient 
response after each individual stimulus was measured using Cytomation Summit software 
(Beckman Coulter), and expressed as a normalized response. Nonlinear regression of 
concentration-response curves was performed with GraphPad Prism using the normalized 
response at each [Ca2+]e for each separate experiment for the determination of the EC50 (i.e. 
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[Ca2+]e required for 50% of the maximal response). Assays were performed in 4-8 
independent transfections. Statistical analysis was performed using the F-test. 
  
Luciferase reporter assays 
HEK-CaSR cells were plated in 24-well plates and transiently transfected with 100 ng/ml 
pBI-CMV2-GNA11 WT or mutant construct, 100 ng/ml luciferase construct (either pGL4-
nuclear factor of activated T-cells-response element (NFAT-RE) or pGL4-serum response 
element (SRE) and 10 ng/ml pRL null control luciferase reporter. Following 48 hours 
incubation, cells were treated with SFM overnight. Cells were then treated with SFM 
containing 0.1-10 mM CaCl2 and incubated for 4 hours. Cells were lysed and assays 
performed using Dual-Glo Luciferase (Promega) on a Veritas Luminometer (Promega) as 
previously described (16,18). Luciferase:renilla ratios were expressed as fold changes 
relative to responses at low CaCl2 concentrations (0.1 mM). For studies with NPS 2143 
(Abcam), drug was added to cells four hours before reporter assays were performed. All 
assay conditions were performed in 4-12 independent transfections. Statistical analysis was 
performed by 2-way ANOVA with Tukey’s multiple-comparisons test using GraphPad Prism 
6.  
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RESULTS 
 
Identification of novel missense mutations in Gα11 in two ADH2 probands 
DNA sequence analyses in the two ADH families identified abnormalities only in the GNA11 
gene. Thus, in family 1 (Fig. 2A), a heterozygous G-to-A transition at nucleotide c.196 within 
exon 2 of GNA11 (Fig 1B. and 2C) was identified and in family 2 (Fig. 2B), a heterozygous 
G-to-A transition at nucleotide c.446 within exon 3 of GNA11 was identified (Fig. 1B and 2D). 
The G-to-A transition in family 1 is predicted to lead to a missense substitution of Gly to Ser 
at codon 66 of the Gα11 protein (Fig. 2E), and in family 2 to a missense substitution of Arg to 
His at codon 149 of the Gα11 protein (Fig. 2F). Bioinformatic analyses using Polyphen-2 and 
MutationTaster software (22,23) predicted the p.Gly66Ser and p.Arg149His variants to be 
damaging and likely disease causing (Polyphen-2 score 1, MutationTaster score 0.99). The 
p.Arg149His Gα11 variant was not detected in the gnomAD database, whereas, the 
p.Gly66Ser variant was detected in 2 out of a total of 281,488 alleles, yielding a rare allele 
frequency of <0.001%. The p.Gly66Ser and p.Arg149His variants were detected in all 
hypocalcemic members of families 1 and 2, respectively (Fig. 2A and 2B), and these findings 
with the demonstration of evolutionary conservation of the Gly66 and Arg149 residues in 
Gα11 orthologs and Gα paralogs (Fig. 3A-B), indicated that the p.Gly66Ser and p.Arg149His 
abnormalities likely represented pathogenic mutations rather than benign polymorphic 
variants. Thus, two heterozygous novel missense germline mutations (Fig. 2C-F) were likely 
identified in the two ADH families, and structural and functional characterisation of these 
potential Gα11 mutations were therefore undertaken.  
 
Structural Characterization of the p.Gly66Ser and p.Arg149His Gα11 mutant proteins 
The Gly66 residue is located within the linker 1 peptide that acts as a flexible hinge between 
the helical and GTPase domains of Gα11 and connects the α1 helix of the GTPase domain 
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with the αA helix of the helical domain (Figs. 1C, 3A and 3C-D). The linker 1 peptide 
comprises five residues that form a hydrogen bond network with residues within the α1- and 
αA-helices to stabilise the G-protein structure (27) (Figs. 1C and 3C). The Gly66 residue 
represents the central amino acid of the linker 1 peptide and forms a hydrogen bond with the 
Arg60 residue (27), mutations of which have been reported to cause ADH2 (Figs. 1 and 3C) 
(9,10). However, the Ser66 mutation is not predicted to disrupt the interaction with the Arg60 
residue (Fig. 3D), but the mutant Ser66 residue instead leads to the introduction of a bulky 
polar side chain (Fig. 3D), which may destabilise the linker 1 region.  
 
The Arg149 residue is located within the αD helix of the helical domain, which lies close to 
switch 3, a flexible region within the GTPase domain that undergoes conformational changes 
during Gα11 activation (28) (Figs. 1C, 3A and 3E). Arg149 projects into the interdomain 
interface and is predicted to form two contacts (dotted black line) with the switch 3 Asp236 
residue (Fig. 3E). Mutation of the Arg149 residue to His149 is predicted to lose both contacts 
with the Asp236 residue (Fig. 3F).  
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Functional Characterization of the p.Gly66Ser and p.Arg149His Gα11 mutant proteins 
The effects of the p.Gly66Ser and p.Arg149His mutations on Gα11 function could not be 
predicted from the homology modelling studies described above, and we therefore 
characterised these mutations in vitro to determine their effects on CaSR-mediated 
signaling. HEK-CaSR cells were transiently transfected with pBI-CMV2-GNA11 constructs 
expressing either the WT (Gly66 or Arg149) or mutant (Ser66 or His149) Gα11 proteins. This 
bidirectional pBI-CMV2 vector allows for co-expression of Gα11 and GFP at equivalent levels 
(2); and expression of the CaSR, Gα11 and GFP was confirmed by fluorescence microscopy 
and/or Western blot analyses (Fig. 4A-B). Gα11 expression was shown to be similar in cells 
transiently transfected with WT or mutant proteins, and greater in transfected cells than 
endogenous Gα11 protein expression in untransfected cells, by Western blot analyses in 
which calnexin was used as a loading control (Fig. 4B). 
 
Effect of the p.Gly66Ser and p.Arg149His Gα11 mutant proteins on CaSR-mediated Ca
2+
i 
responses 
 
The effects of the Gα11 mutants, Ser66 and His149, on Ca
2+
e-induced Ca
2+
i responses using 
the Fluo-4 calcium assay were assessed, as reported (16). The Ca2+i responses in WT and 
mutant Gα11-expressing cells were shown to increase in a dose-dependent manner following 
stimulation with increasing concentrations of Ca2+e. The responses of the mutant Ser66 and 
His149 expressing cells were similar to WT cells at low (0.1 mM) Ca2+e, but were significantly 
elevated compared to WT cells following Ca2+e stimulation (Fig. 4C-D). Thus, the Ser66 and 
His149 mutant expressing cells showed a leftward shift in the concentration-response curve 
(Fig. 4C-D), with significantly reduced mean EC50 values (p<0.0001, n = 4-8) of 2.21 mM 
(95% confidence interval (CI) 2.08-2.34 mM) for Ser66, and of 2.22 mM (95% CI 2.08-2.37 
mM) for His149 expressing cells, compared to 2.81 mM (95% CI 2.66-2.97 mM) for WT 
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expressing cells (Fig. 4C-D), consistent with a gain-of-function of the Gα11 mutants. Addition 
of 10nM of the negative allosteric modulator NPS 2143 was able to increase the EC50 of the 
mutant cells to a value of 2.87 mM (95% CI 2.70-3.05 mM) for the Ser66 expressing cells 
and to 2.79 mM (95% CI 2.56-3.04 mM) for the His149 cells, such that the responses were 
not significantly different to WT expressing cells (Fig. 4C-D). Addition of NPS 2143 at the 
higher 30 nM dose increased the EC50 of the Ser66 and His149 mutant cells to values of 
3.74 mM (95% CI 3.65-3.83 mM), and 3.44 mM (95% CI 3.25-3.65 mM), respectively, which 
were significantly greater than that of untreated WT cells (p<0.0001, Fig. 4C-D). Therefore, a 
10 nM dose of NPS 2143 is effective at normalizing Ser66 and His149 Ca2+i responses, 
whereas 30mM of NPS 2143 leads to a dose-dependent ‘over-correction’ that is equivalent 
to a loss-of-function of the CaSR. 
 
To provide further evidence that the Ser66 and His149 Gα11 mutant proteins affect Ca
2+
i 
signaling, the gene transcription induced by a NFAT-RE containing luciferase reporter 
construct was measured, as NFAT is a downstream mediator of Ca2+i signaling (29) (Fig. 
1A). HEK-CaSR cells were transiently transfected with WT or mutant Ser66 or His149 
mutant Gα11 proteins, and NFAT-RE reporter fold-change responses measured in response 
to increasing concentrations of Ca2+e. NFAT-RE reporter responses were significantly 
elevated in cells expressing the Ser66 and His149 mutant Gα11 proteins (Fig. 5A-B). The 
effects of 10 nM NPS 2143 on these NFAT-RE responses were assessed at 7.5mM Ca2+e 
concentration. This confirmed the significantly increased NFAT-RE reporter fold-change 
responses in Ser66 and His149 cells, compared to WT expressing cells (Ser66 = 4.12±0.27 
and His149 = 4.85±0.45, compared to 2.26±0.06 for WT expressing cells, p<0.001 and 
p<0.0001, respectively) and demonstrated that addition of 10 nM NPS 2143 to the cells 
rectified NFAT-RE reporter fold-change responses to WT values (Ser66 + 10 nM NPS 2143 
= 2.63±0.09 and His149 + 10 nM NPS 2143 = 2.92±0.06) (Fig. 5C-D).    
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Effect of the p.Gly66Ser and p.Arg149His Gα11 mutant proteins on CaSR-mediated MAPK 
responses 
 
Previous studies of Gα11 mutations have demonstrated an increase in MAPK signaling in 
cells expressing ADH2-causing mutant proteins (9,17). To investigate the effect of the Ser66 
and His149 mutant proteins on MAPK signaling, gene transcription induced by a SRE 
containing luciferase reporter construct, which is a downstream mediator of MAPK signaling 
(21) (Fig. 1A), was measured in HEK-CaSR cells transiently expressing WT or mutant Ser66 
or His149 Gα11 proteins (Fig. 6A-B). Cells expressing the Ser66 and His149 mutant proteins 
showed no alterations in SRE reporter fold-change responses at low (0.1mM) Ca2+e (Fig. 6A-
B). However, stimulation with increasing Ca2+e concentrations led to significantly elevated 
SRE reporter fold-change responses at 2.5-10 mM Ca2+e in cells expressing the Ser66 and 
His149 Gα11 mutants compared to WT expressing cells (Fig. 6A-B). The effects of 10nM 
NPS 2143 on these SRE responses were assessed at 7.5 mM Ca2+e concentration. This 
revealed that the SRE reporter fold-change responses in Ser66 and His149 expressing cells 
were significantly elevated compared to WT expressing cells (Ser66 = 7.86±1.28, compared 
to 3.21±0.32 for WT expressing cells, p<0.0001, and His149 = 13.26±0.85, compared  to 
9.56±1.18 for WT, p<0.01) (Fig. 6C-D), while addition of 10 nM NPS-2143 to the Gα11 
mutant expressing cells rectified SRE reporter responses to that of WT Gα11 expressing cells 
(Ser66 + 10 nM NPS-2143 = 3.96±0.16; and His149 + 10 nM NPS-2143 = 10.15±0.57) (Fig. 
6C-D). Thus, a 10 nM dose of NPS-2143 is effective at normalizing mutant Gα11 Ser66 and 
His149 MAPK responses.  
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DISCUSSION 
Our studies have identified two novel heterozygous germline Gα11 mutations associated with 
ADH2. The affected individuals harboring the gain-of-function p.Gly66Ser and p.Arg149His 
Gα11 mutations had a generally mild clinical phenotype with serum calcium concentrations of 
>1.90 mmol/L and were either asymptomatic or experienced paraesthesiae. In addition, 
there were no alterations in serum concentrations of phosphate or magnesium, and plasma 
PTH concentrations were detectable and inappropriately within the normal range. These 
findings are similar to that reported for other patients with ADH2, which is characterised by 
mild-to-moderate hypocalcemia, normal or elevated serum phosphate, normomagnesemia 
and low/normal PTH values (2,9-12). Urinary calcium excretion was normal or low in the 
affected individuals in this report, which is also consistent with the phenotype of ADH2. 
However, it should be noted that some ADH2 patients are susceptible to treatment-related 
hypercalciuria, nephrocalcinosis and nephrolithiasis (9,11,12). 
 
The p.Gly66Ser and p.Arg149His Gα11 mutations reported in this study are located at the 
interface between the GTPase and helical domains (Figs. 1 and 3). The interdomain 
interface represents a highly conserved region of the Gα subunit (30), and is the site of 
multiple interactions between the GTPase and helical domains, including between the linker 
1 peptide and the α1 and αA helices (27), and also between the αD-helix and the switch III 
region (31). This region has a critical structural role within the G-protein and is important for 
binding guanine nucleotides. In support of this, engineered mutations of the Gα subunit 
interdomain interface residues have been shown to destabilise the GDP-bound state, and it 
is likely that such mutations enhance the separation of the GTPase and helical domains, 
which in turn leads to the release of GDP (30). The interdomain interface region has 
previously been associated with four germline mutations of Gα11, three associated with 
ADH2 (p.Arg60Cys, p.Arg60Leu and p.Arg181Gln), and one associated with FHH2 
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(p.Thr54Met) (Fig. 1) (2,9,10,15). Additionally, the germline Gα11 hypermorphic variant, 
p.Ile62Val, identified in an N-ethyl-N-nitrosourea (ENU) generated mouse which is a model 
for ADH2, and the somatic constitutively activating mutations in Gα11 identified in patients 
with uveal melanoma, also affect the interdomain interface (18,32,33). Thus, this region 
likely represents a hotspot for disease-causing Gα11 mutations.  
 
Our finding that the germline p.Gly66Ser and p.Arg149His Gα11 mutations lead to a gain-of-
function contrasts with engineered mutagenesis studies involving homologous residues in 
other Gα subunits (27,31). Thus, an engineered p.Gly66Asp mutation in the closely-related 
Gαq protein did not cause a gain-of-function, but instead increased coupling of non-Gq-
GPCRs to Gq effectors (27,34). The Gly66 residue is located within the linker 1 peptide, 
which is not fully conserved between the Gα11 and Gαq proteins (Fig. 3A), and this lack of 
sequence conservation may explain the differences observed in these studies. Mutations of 
the αD-helix Asn167 Gαs residue, which is homologous to the Arg149 Gα11 residue, also did 
not lead to a gain-of-function (31). Indeed, an engineered p.Asn167Ala mutation had no 
effect on Gαs function, whereas an engineered p.Asn167Arg mutation impaired GPCR-
mediated activation of Gαs (31). However, mutagenesis studies of Arg144 in Gαi, which is 
homologous to Arg149 in Gα11, did show an increase in GDP dissociation rates, which may 
increase signaling activity (35). Moreover, the Ser140-Asp227 interdomain contact in Gαt, 
equivalent to Gα11 Arg149-Asp236, is important for conformational transitions between 
active and inactive states (36). Thus, it is difficult to predict the structure-function 
consequences of the His149 Gα11 mutation, and the introduction of the mutant residue, 
rather than loss of the wild-type residue in the αD-helix is likely to be responsible for 
influencing Gα subunit function. 
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Our in-vitro studies have shown that that the germline p.Gly66Ser and p.Arg149His Gα11 
mutations do not enhance CaSR-mediated signaling at low (0.1mM) Ca2+e concentrations, 
and thus these mutations are not constitutively activating. This observation is in keeping with 
other reported germline ADH2-causing Gα11 mutations, but contrasts with somatic uveal 
melanoma-causing Gα11 mutations, which cause a marked increase in MAPK activation in 
unstimulated cells (17). The p.Gly66Ser and p.Arg149His Gα11 mutations were associated 
with an overall mild increase in CaSR-mediated Ca2+i and MAPK responses, and these 
findings may explain the mild hypocalcemia observed in the patients harboring these 
mutations. These cellular studies involving the mutant Ser66 and His149 Gα11 proteins have 
also provided further evidence of the utility of calcilytic compounds in rectifying signaling 
abnormalities in the Gα11 protein, which we have previously shown in vitro and in a mouse 
model of ADH2 (17,18). Importantly, our studies showed that a low dose (10nM) of the NPS 
2143 calcilytic compound can successfully correct the gain-of-function associated with both 
the Ser66 and His149 ADH2-causing Gα11 mutations, and this is similar to the p.Arg181Gln 
mutation, which is also located in the interdomain interface (17), but contrasts to the 
p.Phe341Leu mutation, which affects the α5-helix of the GTPase domain that directly binds 
to the GPCR transmembrane domains and intracellular loops, and requires a higher dose 
(30nM) of NPS 2143 to normalize CaSR signaling (17). Thus, mutations affecting residues in 
the interdomain interface require a lower dose of allosteric modulator to rectify CaSR 
signaling than Gα11 mutations located in the G-protein-GPCR interface, and further 
investigation of these may provide insights into the mechanism by which allosteric 
modulators rectify CaSR-mediated signaling abnormalities associated with G-protein 
mutations. 
 
In summary, our studies have identified disease-causing mutations located in the linker 1 
peptide and αD-helix of the Gα11 protein. These findings demonstrate that the Gα11 
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interdomain interface represents a hotspot for germline gain-of-function mutations causing 
ADH2.  
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FIGURES AND TABLES  
Figure 1 
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(A) Diagrammatic representation of the CaSR signaling pathways. Calcium (red circle, Ca) 
binding to CaSR (gray) activates Gα11 (yellow)-dependent stimulation of phospholipase C-β 
(PLCβ) (dark blue), which catalyses formation of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2). IP3 mediates 
calcium mobilisation from intracellular stores, whereas DAG activates the pERK signaling 
cascade. Gene transcription mediated by intracellular calcium and pERK can be measured 
using nuclear factor of activated T-cells response element (NFAT-RE) and serum response 
element (SRE) containing luciferase reporter constructs, respectively. (B) Schematic 
representation of the genomic organisation of the human GNA11 gene which comprises 7 
exons, with coding regions shaded gray and untranslated regions represented by open 
boxes. Loss-of-function Gα11 mutations (orange), have been reported in four FHH2 probands 
(2,15,16), and 6 gain-of-function Gα11 mutations (purple), reported in 7 ADH2 probands (2,9-
12). The Val340Met Gα11 mutation (asterisked) has been reported in two unrelated ADH2 
probands (11,12). This manuscript describes two ADH2 mutations, p.Gly66Ser and 
p.Arg149His (red). The GTPase domain (encoded by portions of exon 1, 2 and 4, and the 
whole of exons 5-7) is connected to the helical domain (encoded by portions of exon 2 and 
4, and the whole of exon 3) by the linker 1 (L1) and linker 2 (L2) peptides. Three flexible 
switch regions (S1-S3), which undergo conformational changes upon Gα11 activation, are 
encoded by exons 4 and 5. (C) Homology model of the Gα11 protein based on the structure 
of Gαq in complex with PLCβ (PDB: 3OHM) (26). The Gα helical (blue) and GTPase (green) 
domains are connected by the linker 1 and linker 2 peptides (gray). GDP (black) is bound at 
the interdomain interface (dashed ellipse). Switch 3 is shown in orange, and the Gly66 and 
Arg149 Gα11 residues that are mutated in families 1 and 2 (Fig. 2), respectively, shown in 
red. Residues previously reported to harbour 6 ADH2 and 4 FHH2 Gα11 mutations are 
shown in purple and orange, respectively (2,9-12,15,16). Adapted from Hannan FM et al J 
Mol Endocrinol 2016 Oct;57(3):R127-42. 
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Figure 2   
 
 
Identification of ADH2 mutations, p.Gly66Ser and p.Arg149His, in Gα11. Pedigrees of (A) 
Family 1 and (B) Family 2, with males and females indicated by squares and circles, 
respectively. Individuals affected with hypocalcemia are indicated by filled symbols; and the 
spouses of individuals I.2 (family 1) and II.2 (family 2), and parents of individuals II.2, II.3 and 
II.4 (family 2) who were not available and therefore their affected status remained unknown 
are shown as open symbols with a question mark. (C) DNA sequence analysis showed the 
hypocalcemic patients (individual II.1 shown) from family 1 to be heterozygous for a G-to-A 
transition at c.196 (red arrow) within exon 2 of GNA11. (D) DNA sequence analyses of the 
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hypocalcemic patients (individual III.1 shown) from family 2 showed them to be 
heterozygous for a G-to-A transition at c.446 (red arrow) within exon 3 of GNA11. (E) The G-
to-A transition in family 1 was predicted to lead to a missense substitution of Gly to Ser at 
codon 66. (F) The G-to-A transition in family 2 was predicted to lead to a missense 
substitution of Arg to His at codon 149. 
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Figure 3   
 
Predicted effects of the p.Gly66Ser and p.Arg149His mutations on the Gα11 protein by 
analysis of evolutionary conservation and structural modeling. (A-B) Multiple protein 
sequence alignment of Gα11-subunit orthologs (top) and Gα-subunit paralogs (bottom), with 
residues comprising the α1 helix, linker 1 peptide (green box) and αA helix shown in A; and 
residues of the αD helix, αD-αE loop and αE helix shown in B. Conserved residues are 
shown in gray, and WT and mutant (m) residue in red in panels A and B.  Gly66 and Arg149 
are highly conserved in Gα11 orthologs and Gα paralogs. (C-D) Homology model of the Gα11 
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protein based on the structure of Gαq in complex with an inhibitor (PDB: 3AH8) (25). (C) The 
WT Gly66, which is a non-polar hydrophobic amino acid, is located within linker 1 and forms 
a contact with Arg60 (purple), which is a positively charged hydrophilic amino acid. (D) 
Mutation of Gly66 to serine (Ser66), a hydrophilic amino acid leads to the introduction of a 
polar side chain, which projects into the cytoplasm and may alter the tight packing of the 
linker 1 region. The contact between Arg60 and Ser66 is unaffected. (E-F) Homology model 
of Gα11 based on the structure of Gαq in complex with the phospholipase C β3 protein (PDB: 
3OHM) (26). (E) The WT Arg149 is located within the αD helix of the helical domain, and 
forms polar contacts (hatched line) with the Asp236 residue in switch 3. (F) Mutation of 
Arg149 to His149, likely causes loss of the polar contact with Asp236, and may affect the 
interaction of the αD-helix with switch 3.  
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 Figure 4  
 
 
Functional characterisation of wild-type (WT) and ADH2-associated mutant Gα11 proteins 
with Gly66Ser and Arg149His substitutions, using intracellular calcium (Ca2+i) responses, 
and assessing the effects of the calcilytic NPS 2143 (2143). (A) Fluorescence microscopy of 
HEK293 cells stably expressing CaSR (HEK-CaSR) and transiently transfected with WT 
(Gly66 and Arg149) or ADH2-associated mutant (m) Ser66 or His149 pBI-CMV2-GNA11 
constructs. UT, untransfected cells. GFP indicates successful transfection and expression of 
Gα11  by these constructs. Bar indicates 10μm. (B) Western blot analysis of CaSR, Gα11 and 
GFP using lysates from HEK-CaSR cells transiently transfected with WT or mutant Ser66 or 
His149 expression constructs. Calnexin was used as a loading control. (C-D) Ca2+i response 
to changes in [Ca2+]e of HEK-CaSR cells transfected with: (C) WT or Ser66 Gα11 mutant or 
(D) WT or His149 Gα11 mutant, measured by Fluo-4 calcium assays. In panels C and D, the 
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Ca2+i responses to changes in [Ca
2+]e are expressed as a percentage of the maximum 
normalized responses and shown as the mean±SEM of 4-8 independent transfections. The 
Ser66 and His149 Gα11 mutants led to a leftward shift in the concentration-response curve 
(solid red line). The addition of 10nM (red dashed line) or 30nM (red dotted line) 2143 
rectified the leftward shift of the Ser66 and His149 Gα11 mutants, when compared to WT 
(black line). The mean half-maximal concentration (EC50) of the responses with 95% 
confidence intervals (CI) and p-values are shown below for each mutant compared to the 
WT response. Statistical analysis was performed using the F-test. ****p<0.0001.  
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Figure 5  
 
NFAT-response element (NFAT-RE) luciferase reporter responses of the Ser66 and His149 
Gα11 mutants and effects of NPS 2143 (2143) treatment. [Ca
2+]e-induced NFAT-RE 
luciferase reporter responses of HEK-CaSR cells transfected with WT (open symbols) or 
mutant (m) (filled symbols) (A) Ser66 or (B) His149 Gα11 proteins. Responses at each [Ca
2+]e 
are expressed as a fold-change of low (0.1mM) [Ca2+]e responses, and shown as 
mean±SEM of 12 independent transfections. NFAT-RE luciferase reporter activity increased 
in all cells in a concentration-dependent manner but was significantly greater in mutant cells. 
Statistical analysis comparing mutant to WT responses by 2-way ANOVA with Tukey’s 
multiple-comparisons test. (C-D) [Ca2+]e-induced NFAT-RE reporter responses to 7.5mM 
Ca2+e in HEK-CaSR cells transfected with WT (open bar) or mutant (filled bar) (C) Ser66 or 
(D) His149 Gα11 proteins. The addition of 10nM NPS 2143 rectified the elevated NFAT-RE 
reporter responses of the mutant (hatched bars) to WT (open bars) levels. Responses are 
expressed as a fold-change of low (0.1mM) [Ca2+]e responses, and shown as mean±SEM of 
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4 independent transfections. Statistical analyses were performed by one-way ANOVA with 
Dunnett’s multiple comparisons test compared to the WT response. ****p<0.0001, 
***p<0.001, *p<0.05 for all panels. 
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Figure 6  
 
SRE luciferase reporter responses of the Ser66 and His149 Gα11 mutants and effects of 
NPS 2143 (2143) treatment. [Ca2+]e-induced SRE luciferase reporter responses of HEK-
CaSR cells transfected with WT (open symbols) or mutant (m) (filled symbols) (A) Ser66 or 
(B) His149 Gα11 proteins. Responses at each [Ca
2+]e are expressed as a fold-change of low 
(0.1mM) [Ca2+]e responses, and shown as mean±SEM of 8 independent transfections. The 
Ser66 and His149 Gα11 mutants led to significantly increased SRE fold-change responses 
following stimulation with Ca2+e compared to WT Gα11. Statistical analysis comparing mutant 
to WT responses by 2-way ANOVA with Tukey’s multiple-comparisons test. (C-D) [Ca2+]e-
induced SRE reporter responses to 7.5mM Ca2+e in HEK-CaSR cells transfected with WT 
(open bar) or mutant (filled bars) (C) Ser66 or (D) His149 Gα11  proteins. The addition of 
10nM NPS 2143 rectified the elevated SRE reporter responses of the mutant (hatched bars) 
to WT (open bars) levels. Responses are expressed as a fold-change of low (0.1mM) [Ca2+]e 
responses, and shown as mean±SEM of 4-8 independent transfections. Statistical analyses 
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were performed by one-way ANOVA with Dunnett’s multiple comparisons test compared to 
the WT response. ****p<0.0001, **p<0.01 for all panels.  
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